-
EP3630114
European procedure
Extract from the Register of European Patents
EP About this file: EP3630114
| EP3630114 - MIGALASTAT FOR TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT [Right-click to bookmark this link] | |||
| Former [2020/15] | METHODS OF TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT | ||
| [2022/35] | Status | The patent has been granted Status updated on 29.09.2023 Database last updated on 24.08.2024 | |
| Former | Grant of patent is intended Status updated on 22.06.2023 | ||
| Former | Examination is in progress Status updated on 04.10.2022 | ||
| Former | Grant of patent is intended Status updated on 22.08.2022 | ||
| Former | Examination is in progress Status updated on 07.05.2021 | ||
| Former | Request for examination was made Status updated on 06.03.2020 | ||
| Former | The international publication has been made Status updated on 08.12.2018 | ||
| Former | unknown Status updated on 04.07.2018 | Most recent event Tooltip | 12.08.2024 | New entry: Communication of a notice of opposition and request to file observations + time limit | Applicant(s) | For all designated states Amicus Therapeutics, Inc. 3675 Market Street Philadelphia, PA 19104 / US | [2021/14] |
| Former [2020/15] | For all designated states Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, NJ 08512 / US | Inventor(s) | 01 /
CASTELLI, Jeff Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury, New Jersey 08512 / US | [2023/44] |
| Former [2020/15] | 01 /
CASTELLI, Jeff Amicus Therapeutics Inc. 1 Cedar Brook Drive Cranbury, New Jersey 08512 / US | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2023/44] |
| Former [2020/15] | Miller Sturt Kenyon 9 John Street London WC1N 2ES / GB | Application number, filing date | 18733415.6 | 30.05.2018 | [2020/15] | WO2018US35032 | Priority number, date | US201762512458P | 30.05.2017 Original published format: US 201762512458 P | US201862626953P | 06.02.2018 Original published format: US 201862626953 P | [2020/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018222655 | Date: | 06.12.2018 | Language: | EN | [2018/49] | Type: | A1 Application with search report | No.: | EP3630114 | Date: | 08.04.2020 | Language: | EN | The application published by WIPO in one of the EPO official languages on 06.12.2018 takes the place of the publication of the European patent application. | [2020/15] | Type: | B1 Patent specification | No.: | EP3630114 | Date: | 01.11.2023 | Language: | EN | [2023/44] | Search report(s) | International search report - published on: | EP | 06.12.2018 | Classification | IPC: | A61K31/445, A61P13/12 | [2020/15] | CPC: |
A61K31/445 (EP,CN);
A61P13/12 (EP,CN);
C12Y302/01022 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2020/15] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | KH | Not yet paid | MA | Not yet paid | MD | Not yet paid | TN | Not yet paid | Title | German: | MIGALASTAT ZUR BEHANDLUNG VON NIERENBEEINTRÄCHTIGTEN PATIENTEN MIT MORBUS FABRY | [2022/35] | English: | MIGALASTAT FOR TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT | [2022/35] | French: | MIGALASTAT POUR LE TRAITEMENT DE PATIENTS ATTEINTS DE LA MALADIE DE FABRY SOUFFRANTS D'UNE INSUFFISANCE RÉNALE | [2022/35] |
| Former [2020/15] | VERFAHREN ZUR BEHANDLUNG VON NIERENBEEINTRÄCHTIGTEN PATIENTEN MIT MORBUS FABRY | ||
| Former [2020/15] | METHODS OF TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT | ||
| Former [2020/15] | MÉTHODES DE TRAITEMENT DE PATIENTS ATTEINTS DE LA MALADIE DE FABRY SOUFFRANT D'UNE INSUFFISANCE RÉNALE | Entry into regional phase | 02.01.2020 | National basic fee paid | 02.01.2020 | Designation fee(s) paid | 02.01.2020 | Examination fee paid | Examination procedure | 02.01.2020 | Examination requested [2020/15] | 02.01.2020 | Date on which the examining division has become responsible | 12.08.2020 | Amendment by applicant (claims and/or description) | 10.05.2021 | Despatch of a communication from the examining division (Time limit: M04) | 09.09.2021 | Reply to a communication from the examining division | 13.10.2021 | Observations by third parties | 19.01.2022 | Despatch of a communication from the examining division (Time limit: M04) | 23.05.2022 | Reply to a communication from the examining division | 23.08.2022 | Communication of intention to grant the patent | 23.09.2022 | Observations by third parties | 28.09.2022 | Fee for grant paid | 28.09.2022 | Fee for publishing/printing paid | 28.09.2022 | Receipt of the translation of the claim(s) | 04.10.2022 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 07.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 16.02.2023 | Reply to a communication from the examining division | 24.08.2023 | Communication of intention to grant the patent | 25.09.2023 | Fee for grant paid | 25.09.2023 | Fee for publishing/printing paid | 25.09.2023 | Receipt of the translation of the claim(s) | Divisional application(s) | EP22165647.3 / EP4062915 | EP22165669.7 / EP4062916 | EP23189734.9 / EP4245366 | EP23219922.4 / EP4327868 | EP23219933.1 / EP4327869 | EP23219949.7 / EP4324522 | EP24164126.5 / EP4374918 | Opposition(s) | Opponent(s) | 01
31.07.2024
01.08.2024
ADMISSIBLE Teva Pharmaceutical Industries Ltd 124 Dvora HaNevi'a St. 6944020 Tel Aviv / IL Opponent's representative D Young & Co LLP 3 Noble Street London EC2V 7BQ / GB | [2024/36] | 13.08.2024 | Invitation to proprietor to file observations on the notice of opposition | Fees paid | Renewal fee | 14.05.2020 | Renewal fee patent year 03 | 13.05.2021 | Renewal fee patent year 04 | 16.03.2022 | Renewal fee patent year 05 | 14.03.2023 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2012154681 (AMICUS THERAPEUTICS [US], et al); | by applicant | US6274597 | US6583158 | US6589964 | US6599919 | US6916829 | US7141582 | US2010113517 | US8592362 |